Navigation Links
ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
Date:4/4/2011

IRVINE, Calif., April 4, 2011 /PRNewswire/ --ChromaDex Corporation (OTCBB: CDXC),an innovative natural products company that provides proprietary, science-based solutions and ingredients, today announced that Curtis A. Lockshin, Ph.D., was appointed to its Board of Directors.

Dr. Lockshin currently serves as a Director of Sorrento Therapeutics and the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Winston Pharmaceuticals. In addition to his board positions, he serves as a consultant to private companies in healthcare and biotechnology. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.

"Dr. Lockshin's deep experience with an array of science-based, regulated companies brings valuable perspective to our board," said Frank Jaksch, CEO and co-founder of ChromaDex. "As we convert our knowledge of natural compounds into innovative commercial products and applications targeted at the nutraceutical, food and beverage, cosmetic and pharmaceutical markets, we are committed to strengthening our management team and our board with the experience needed to reinforce our dedication to the science behind our natural ingredients."

About ChromaDex

ChromaDex™ is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has a strong pipeline of new compounds, including its pTeroPure™ pterostilbene on which it has worldwide, exclusive rights to patents pending.  ChromaDex is a publicly-traded life-sciences company (OTC stock symbol CDXC.OB).

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the company's Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Inquiries
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

ChromaDex Contact
Jenny Robles
949-419-0288
jennyr@chromadex.com

Media Contact
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
2. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Announces 2008 Year End Financial Results
5. ChromaDex Announces Second Quarter 2008 Financial Results
6. BioStorage Technologies Appoints New Director of Business Development for European Operations
7. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
8. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
9. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
10. Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality
11. OncoSec Medical Appoints Punit Dhillon as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... of multiple immunoassay-based threat detection technologies by researchers from the Pacific National ... threat detection technology was found to have the best level of detection ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):